NASDAQ · Biotechnology

FibroGen, Inc. (FGEN) Stock

$9.07 -1.63% NASDAQ: FGEN Healthcare

FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments.

Valuation

MetricValue
Price$9.07
Market Cap$36.69M
P/E Ratio0.22
P/B Ratio-3.95
P/S Ratio4.93
EPS (TTM)$41.23
52-Week High$21.95
52-Week Low$4.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-267.30%
ROA149.24%
ROCE-54.95%
Gross Margin65.66%
Operating Margin-602.22%
Net Margin3050.00%
Debt/Equity0.00
Current Ratio3.61

Annual Financials (USD)

Metric20212022202320242025
Revenue$235.0M$141.0M$47.0M$30.0M$6.0M
Operating Profit$-289.0M$-301.0M$-323.0M$-150.0M$-46.0M
Net Profit$-290.0M$-294.0M$-284.0M$-48.0M$183.0M
EPS$-3.15$-3.15$-2.92$-0.48$45.37
Op Margin-122.6%-213.9%-689.5%-507.8%-712.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$774.0M$610.0M$424.0M$215.0M$120.0M
Total Liabilities$545.0M$612.0M$586.0M$398.0M$115.0M
Cash$171.0M$156.0M$114.0M$50.0M$48.0M
Borrowings$100.0M$90.0M$170.0M$90.0M$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-82.0M$-146.0M$-315.0M$-138.0M$-5.0M
Investing Cash Flow$-457.0M$50.0M$151.0M$126.0M$35.0M
Financing Cash Flow$-7.0M$43.0M$1.0M$2.0M$-82.0M
Net Cash Flow$-507.0M$-16.0M$-42.0M$-12.0M$-54.0M
Free Cash Flow$-112.0M$-185.0M$-318.0M$-138.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.01
FCF Yield-58.33%
Quick Ratio3.48
Interest Coverage-11.89
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%
MRSNMersana Therapeutics, Inc. $29.08 +0.00% -2.59 $145.36M 0.00%

About FibroGen, Inc.

FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.

FibroGen, Inc. is headquartered in US.

FibroGen, Inc. (FGEN) stock trades at $9.07 with a market capitalization of $36.69M. The stock is valued at a price-to-earnings (P/E) ratio of 0.22, price-to-book of -3.95, price-to-sales of 4.93. Over the past 52 weeks the stock has ranged between $4.85 and $21.95, and currently trades 58.7% below its 52-week high.

On profitability, FibroGen, Inc. generates a return on equity (ROE) of -267.30%, return on capital employed of -54.95%, an operating margin of -602.22%, a net profit margin of 3050.00%.

Official website: www.fibrogen.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides